These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 326277

  • 1. [Effect of MK-486 alone on Parkinsonism; studies on the clinical symptoms and catecholamine concentrations in the blood, urine and cerebrospinal fluid].
    Tohgi H, Ogawa M.
    No To Shinkei; 1977 Feb; 29(2):205-13. PubMed ID: 326277
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Levodopa, carbidopa, and pyridoxine in Parkinson disease. Metabolic interactions.
    Mars H.
    Arch Neurol; 1974 Jun; 30(6):444-7. PubMed ID: 4827061
    [No Abstract] [Full Text] [Related]

  • 4. MK 486 and levodopa in treatment of Parkinsonism.
    Lieberman AN, Derby BM, Feigenson J, Goodgold A, Nesbitte J, Resurreccion EC, Valdivia F.
    Dis Nerv Syst; 1973 Jun; 34(4):167-71. PubMed ID: 4711885
    [No Abstract] [Full Text] [Related]

  • 5. Levodopa and dopamine in cerebrospinal fluid.
    Papavasiliou PS, Cotzias GC, Lawrence WH.
    Neurology; 1973 Jul; 23(7):756-9. PubMed ID: 4736493
    [No Abstract] [Full Text] [Related]

  • 6. A double-blind controlled study of MK-486 in Parkinson's disease.
    Schwartz AM, Olanow CW, Spencer A.
    Trans Am Neurol Assoc; 1973 Jul; 98():301-3. PubMed ID: 4594189
    [No Abstract] [Full Text] [Related]

  • 7. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y, Yoshida M, Obayashi T, Ueki A.
    Rinsho Shinkeigaku; 1976 Jul 01; 16(7):511-9. PubMed ID: 986921
    [No Abstract] [Full Text] [Related]

  • 8. [Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
    Geissbuhler F, Bartholini G, Gaillard JM, Tissot R.
    Encephale; 1971 Jul 01; 60(3):189-209. PubMed ID: 5119348
    [No Abstract] [Full Text] [Related]

  • 9. Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report.
    Savery F.
    Curr Ther Res Clin Exp; 1976 Mar 01; 19(3):337-8. PubMed ID: 817863
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
    Pullar IA, Dowson JH, Ahmed R, Chow R, Gillingham FJ.
    Confin Neurol; 1972 Mar 01; 34(2):143-8. PubMed ID: 4666057
    [No Abstract] [Full Text] [Related]

  • 12. An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy.
    Mones RJ.
    J Neurol Neurosurg Psychiatry; 1973 Jun 01; 36(3):362-7. PubMed ID: 4714098
    [Abstract] [Full Text] [Related]

  • 13. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease.
    Olanow CW, Gauger LL, Cedarbaum JM.
    Ann Neurol; 1991 May 01; 29(5):556-9. PubMed ID: 1859185
    [Abstract] [Full Text] [Related]

  • 14. "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.
    Fahn S.
    Neurology; 1974 May 01; 24(5):431-41. PubMed ID: 4857104
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of alpha methyl dopa and alpha methyl dopa hydrazine with L-dopa therapy.
    Mones RJ.
    N Y State J Med; 1974 Jan 01; 74(1):47-51. PubMed ID: 4591989
    [No Abstract] [Full Text] [Related]

  • 16. [Results of the treatment of Parkinson's diseases with carbidopa and L-Dopa].
    Cáceres AF.
    Rev Fac Cienc Med Cordoba; 1974 Jan 01; 32(2):161-74. PubMed ID: 4619691
    [No Abstract] [Full Text] [Related]

  • 17. [Madopar in the treatment of paralysis agitans: II. TRH activation test, EMG examination and HVA level in cerebrospinal fluid before and after treatment].
    Liu DK.
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1980 Apr 01; 13(4):223-6. PubMed ID: 6790255
    [No Abstract] [Full Text] [Related]

  • 18. Metabolism and clinical assessment of L-dopa in parkinsonism.
    Ericsson AD, McCann D, Sharpless N, Reveno W.
    Neurology; 1970 Apr 01; 20(4):402. PubMed ID: 4935027
    [No Abstract] [Full Text] [Related]

  • 19. Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose.
    Granerus AK, Jagenburg R, Rödjer S, Svanborg A.
    Acta Med Scand; 1974 Dec 01; 196(6):459-63. PubMed ID: 4456974
    [No Abstract] [Full Text] [Related]

  • 20. Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia-parkinsonism.
    Brashear A, Butler IJ, Hyland K, Farlow MR, Dobyns WB.
    Ann Neurol; 1998 Apr 01; 43(4):521-6. PubMed ID: 9546335
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.